Cargando…

The Effect of Phosphodiesterase-type 5 Inhibitors on Erectile Function: An Overview of Systematic Reviews

Background: Multiple systematic reviews explore the effect of phosphodiesterase type 5 (PDE5) inhibitors on erectile dysfunction (ED), with each study addressing specific outcomes. However, physicians and policymakers require a holistic approach of this topic. Objective: To summarize the current evi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pyrgidis, Nikolaos, Mykoniatis, Ioannis, Haidich, Anna-Bettina, Tirta, Maria, Talimtzi, Persefoni, Kalyvianakis, Dimitrios, Ouranidis, Andreas, Hatzichristou, Dimitrios
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8452927/ https://www.ncbi.nlm.nih.gov/pubmed/34557099 http://dx.doi.org/10.3389/fphar.2021.735708

Ejemplares similares

Effect of phosphodiesterase-type 5 inhibitors on erectile function: an overview of systematic reviews and meta-analyses
por: Pyrgidis, Nikolaos, et al.
Publicado: (2021)

Assessment of Combination Therapies vs Monotherapy for Erectile Dysfunction: A Systematic Review and Meta-analysis
por: Mykoniatis, Ioannis, et al.
Publicado: (2021)

A comprehensive narrative review of residual curvature correction during penile prosthesis implantation in patients with severe erectile dysfunction and concomitant Peyronie’s disease
por: Sokolakis, Ioannis, et al.
Publicado: (2021)

Sildenafil 4.0—Integrated Synthetic Chemistry, Formulation and Analytical Strategies Effecting Immense Therapeutic and Societal Impact in the Fourth Industrial Era
por: Ouranidis, Andreas, et al.
Publicado: (2021)

Are endourological procedures for nephrolithiasis treatment associated with renal injury? A review of potential mechanisms and novel diagnostic indexes
por: Mykoniatis, Ioannis, et al.
Publicado: (2020)

Repurposing phosphodiesterase-5 inhibitors as chemoadjuvants
por: Tiwari, Amit K., et al.
Publicado: (2013)

Erectile dysfunction and heart failure: the role of phosphodiesterase type 5 inhibitors
por: Al-Ameri, H, et al.
Publicado: (2009)

Preference for and adherence to oral phosphodiesterase-5 inhibitors in the treatment of erectile dysfunction
por: Giannitsas, Konstantinos, et al.
Publicado: (2008)

Chronic Low Dosing of Phosphodiesterase Type 5 Inhibitor for Erectile Dysfunction
por: Sung, Hyun Hwan, et al.
Publicado: (2012)

The effect of standard percutaneous nephrolithotomy, miniaturized percutaneous nephrolithotomy and retrograde intrarenal surgery on biomarkers of renal injury: a randomized clinical trial
por: Memmos, Dimitrios, et al.
Publicado: (2023)

Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases
por: Li, Heng, et al.
Publicado: (2018)

Phosphodiesterase 4 Inhibitors in Allergic Rhinitis/Rhinosinusitis
por: Janosova, Viera, et al.
Publicado: (2020)

Respiratory Cilia as a Therapeutic Target of Phosphodiesterase Inhibitors
por: Joskova, Marta, et al.
Publicado: (2020)

Phosphodiesterase-4 Inhibitors for Non-COPD Respiratory Diseases
por: Kawamatawong, Theerasuk
Publicado: (2021)

Endothelial Dysfunction, Erectile Dysfunction and Phosphodiesterase 5 Inhibitors. An Update of the Current Data and Future Perspectives
por: Konstantinopoulos, Angelis, et al.
Publicado: (2007)

Phosphodiesterase type 5 inhibitors as a treatment for erectile dysfunction: Current information and new horizons
por: Ferguson, James E., et al.
Publicado: (2013)

A comparison of the available phosphodiesterase-5 inhibitors in the treatment of erectile dysfunction: a focus on avanafil
por: Evans, Jeffery D, et al.
Publicado: (2015)

The devil is in the details: an analysis of the subtleties between phosphodiesterase inhibitors for erectile dysfunction
por: Smith-Harrison, L.I., et al.
Publicado: (2016)

Pathophysiology of visual disorders induced by phosphodiesterase inhibitors in the treatment of erectile dysfunction
por: Moschos, Marilita M, et al.
Publicado: (2016)

Inhaled Phosphodiesterase 4 (PDE4) Inhibitors for Inflammatory Respiratory Diseases
por: Phillips, Jonathan E.
Publicado: (2020)

Efficacy and Safety of Platelet-Rich Plasma Injections for the Treatment of Female Sexual Dysfunction and Stress Urinary Incontinence: A Systematic Review
por: Dankova, Irina, et al.
Publicado: (2023)

Tadalafil 5 mg once daily for the treatment of erectile dysfunction during a 6-month observational study (EDATE): impact of patient characteristics and comorbidities
por: Hatzichristou, Dimitrios, et al.
Publicado: (2015)

Toward a new ‘EPOCH’: optimising treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunction
por: Sadovsky, R, et al.
Publicado: (2009)

Phosphodiesterase type 5 inhibitors for the treatment of post-nerve sparing radical prostatectomy erectile dysfunction in men
por: Li, Jinhong, et al.
Publicado: (2014)

Inflammatory biomarkers may predict response to phosphodiesterase type 5 inhibitor treatment in patients with erectile dysfunction
por: Kilic, Metin, et al.
Publicado: (2023)

Substrate-Dependence of Competitive Nucleotide Pyrophosphatase/Phosphodiesterase1 (NPP1) Inhibitors
por: Lee, Sang-Yong, et al.
Publicado: (2017)

Recent developments of phosphodiesterase inhibitors: Clinical trials, emerging indications and novel molecules
por: Bondarev, Andrey D., et al.
Publicado: (2022)

The role of Phosphodiesterase-1 and its natural product inhibitors in Alzheimer’s disease: A review
por: Ahmad, Nazir, et al.
Publicado: (2022)

Acute effect of phosphodiesterase type 5 inhibitor on serum oxidative status and prolidase activities in men with erectile dysfunction
por: Savas, Murat, et al.
Publicado: (2010)

Let’s rethinking about the safety of phosphodiesterase type 5 inhibitor in the patients with erectile dysfunction after radical prostatectomy
por: Kim, Su Jin, et al.
Publicado: (2016)

Effect of a three-piece inflatable penile prosthesis combined with a phosphodiesterase-5 inhibitor on erectile dysfunction
por: Wang, Jian, et al.
Publicado: (2021)

The effectiveness of psychological interventions alone, or in combination with phosphodiesterase-5 inhibitors, for the treatment of erectile dysfunction:A systematic review
por: Atallah, Sandrine, et al.
Publicado: (2021)

High frequency of potential phosphodiesterase type 5 inhibitor drug interactions in males with HIV infection and erectile dysfunction
por: Cota, Jason M., et al.
Publicado: (2021)

Design and Validation of a Novel Smartphone-Based Visual Acuity Test: The K-VA Test
por: Karampatakis, Vasileios, et al.
Publicado: (2023)

Adherence to Phosphodiesterase Type 5 Inhibitors in the Treatment of Erectile Dysfunction in Long-Term Users: How Do Men Use the Inhibitors?
por: Carvalheira, Ana, et al.
Publicado: (2014)

Improvement in duration of erection following phosphodiesterase type 5 inhibitor therapy with vardenafil in men with erectile dysfunction: the ENDURANCE study
por: Rosenberg, M T, et al.
Publicado: (2009)

Patient preference and satisfaction in erectile dysfunction therapy: a comparison of the three phosphodiesterase-5 inhibitors sildenafil, vardenafil and tadalafil
por: Raheem, Amr Abdel, et al.
Publicado: (2009)

A meta-regression evaluating the effectiveness and prognostic factors of oral phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction
por: Yuan, Jin-Qiu, et al.
Publicado: (2016)

Phosphodiesterase type-5 inhibitors for erectile dysfunction following nerve-sparing radical prostatectomy: A network meta-analysis
por: Yang, Jie, et al.
Publicado: (2021)

Erectile dysfunction treatment with phosphodiesterase-5 inhibitors: google trends analysis of last 10 years and covid-19 pandemic
por: Değer, Dr. Müslim D., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_cqu24hfdrsjiebbf56mftg3n8c